The FDA has granted breakthrough device designation to Bio-Techne's ExoDx Prostate Intelliscore test, which is designed to evaluate a man's risk of developing prostate cancer. "This assay [has the] ability to give urologists a more precise, genetically informed understanding of a man's risk for aggressive disease via a simple urine sample, without the need for an invasive prostate tissue biopsy," said Bio-Techne President and CEO Charles Kummeth.
FDA grants breakthrough designation to Bio-Techne prostate cancer test
Sign up for FDLI SmartBrief
News for the food and drug law community
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.